160 related articles for article (PubMed ID: 1374986)
1. Resistance of human immunodeficiency virus type 1 reverse transcriptase to TIBO derivatives induced by site-directed mutagenesis.
de Vreese K; Debyser Z; Vandamme AM; Pauwels R; Desmyter J; de Clercq E; Anné J
Virology; 1992 Jun; 188(2):900-4. PubMed ID: 1374986
[TBL] [Abstract][Full Text] [Related]
2. Kinetics of inhibition of endogenous human immunodeficiency virus type 1 reverse transcription by 2',3'-dideoxynucleoside 5'-triphosphate, tetrahydroimidazo-[4,5,1-jk][1,4]-benzodiazepin-2(1H)-thion e, and 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives.
Debyser Z; Vandamme AM; Pauwels R; Baba M; Desmyter J; De Clercq E
J Biol Chem; 1992 Jun; 267(17):11769-76. PubMed ID: 1376311
[TBL] [Abstract][Full Text] [Related]
3. A single conservative amino acid substitution in the reverse transcriptase of human immunodeficiency virus-1 confers resistance to (+)-(5S)-4,5,6,7-tetrahydro-5-methyl-6-(3-methyl-2-butenyl)imidazo[4,5, 1- jk][1,4]benzodiazepin-2(1H)-thione (TIBO R82150).
Mellors JW; Im GJ; Tramontano E; Winkler SR; Medina DJ; Dutschman GE; Bazmi HZ; Piras G; Gonzalez CJ; Cheng YC
Mol Pharmacol; 1993 Jan; 43(1):11-6. PubMed ID: 7678690
[TBL] [Abstract][Full Text] [Related]
4. Common features in the interaction of tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione and 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives with the human immunodeficiency virus type 1 reverse transcriptase.
Debyser Z; Pauwels R; Baba M; Desmyter J; De Clercq E
Mol Pharmacol; 1992 May; 41(5):963-8. PubMed ID: 1375320
[TBL] [Abstract][Full Text] [Related]
5. Differential inhibitory effects of TIBO derivatives on different strains of simian immunodeficiency virus.
Debyser Z; De Vreese K; Pauwels R; Yamamoto N; Anné J; De Clercq E; Desmyter J
J Gen Virol; 1992 Jul; 73 ( Pt 7)():1799-804. PubMed ID: 1378481
[TBL] [Abstract][Full Text] [Related]
6. Resistance of HIV-1 reverse transcriptase against [2',5'-bis-O-(tert-butyldimethylsilyl)-3'-spiro-5''-(4''-amino-1'',2''- oxathiole-2'',2''-dioxide)] (TSAO) derivatives is determined by the mutation Glu138-->Lys on the p51 subunit.
Jonckheere H; Taymans JM; Balzarini J; Velázquez S; Camarasa MJ; Desmyter J; De Clercq E; Anné J
J Biol Chem; 1994 Oct; 269(41):25255-8. PubMed ID: 7523383
[TBL] [Abstract][Full Text] [Related]
7. New tetrahydroimidazo[4,5,1-jk][1,4]-benzodiazepin-2(1H)-one and -thione derivatives are potent inhibitors of human immunodeficiency virus type 1 replication and are synergistic with 2',3'-dideoxynucleoside analogs.
Pauwels R; Andries K; Debyser Z; Kukla MJ; Schols D; Breslin HJ; Woestenborghs R; Desmyter J; Janssen MA; De Clercq E
Antimicrob Agents Chemother; 1994 Dec; 38(12):2863-70. PubMed ID: 7535037
[TBL] [Abstract][Full Text] [Related]
8. 3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors.
Larder BA
Antimicrob Agents Chemother; 1992 Dec; 36(12):2664-9. PubMed ID: 1282792
[TBL] [Abstract][Full Text] [Related]
9. Kinetic and mutational analysis of human immunodeficiency virus type 1 reverse transcriptase inhibition by inophyllums, a novel class of non-nucleoside inhibitors.
Taylor PB; Culp JS; Debouck C; Johnson RK; Patil AD; Woolf DJ; Brooks I; Hertzberg RP
J Biol Chem; 1994 Mar; 269(9):6325-31. PubMed ID: 7509800
[TBL] [Abstract][Full Text] [Related]
10. Kinetics of different human immunodeficiency virus type 1 reverse transcriptases resistant to human immunodeficiency virus type 1-specific reverse transcriptase inhibitors.
Debyser Z; De Vreese K; Knops-Gerrits PP; Baekelandt V; Bhikhabhai R; Strandberg B; Pauwels R; Anné J; Desmyter J; De Clercq E
Mol Pharmacol; 1993 Apr; 43(4):521-6. PubMed ID: 7682649
[TBL] [Abstract][Full Text] [Related]
11. Kinetics of inhibition of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase by the novel HIV-1-specific nucleoside analogue [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5 "- (4"-amino-1",2"-oxathiole-2",2"-dioxide)thymine (TSAO-T).
Balzarini J; Pérez-Pérez MJ; San-Félix A; Camarasa MJ; Bathurst IC; Barr PJ; De Clercq E
J Biol Chem; 1992 Jun; 267(17):11831-8. PubMed ID: 1376314
[TBL] [Abstract][Full Text] [Related]
12. An antiviral target on reverse transcriptase of human immunodeficiency virus type 1 revealed by tetrahydroimidazo-[4,5,1-jk] [1,4]benzodiazepin-2 (1H)-one and -thione derivatives.
Debyser Z; Pauwels R; Andries K; Desmyter J; Kukla M; Janssen PA; De Clercq E
Proc Natl Acad Sci U S A; 1991 Feb; 88(4):1451-5. PubMed ID: 1705038
[TBL] [Abstract][Full Text] [Related]
13. Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant.
Das K; Ding J; Hsiou Y; Clark AD; Moereels H; Koymans L; Andries K; Pauwels R; Janssen PA; Boyer PL; Clark P; Smith RH; Kroeger Smith MB; Michejda CJ; Hughes SH; Arnold E
J Mol Biol; 1996 Dec; 264(5):1085-100. PubMed ID: 9000632
[TBL] [Abstract][Full Text] [Related]
14. Interaction of the reverse transcriptase of human immunodeficiency virus type 1 with DNA.
Bakhanashvili M; Hizi A
Biochemistry; 1994 Oct; 33(40):12222-8. PubMed ID: 7522556
[TBL] [Abstract][Full Text] [Related]
15. Amino acid substitutions in HIV-1 reverse transcriptase with corresponding residues from HIV-2. Effect on kinetic constants and inhibition by non-nucleoside analogs.
Bacolla A; Shih CK; Rose JM; Piras G; Warren TC; Grygon CA; Ingraham RH; Cousins RC; Greenwood DJ; Richman D
J Biol Chem; 1993 Aug; 268(22):16571-7. PubMed ID: 7688367
[TBL] [Abstract][Full Text] [Related]
16. Enzymatic properties of two mutants of reverse transcriptase of human immunodeficiency virus type 1 (tyrosine 181-->isoleucine and tyrosine 188-->leucine), resistant to nonnucleoside inhibitors.
Loya S; Bakhanashvili M; Tal R; Hughes SH; Boyer PL; Hizi A
AIDS Res Hum Retroviruses; 1994 Aug; 10(8):939-46. PubMed ID: 7529032
[TBL] [Abstract][Full Text] [Related]
17. Allosteric inhibition of human immunodeficiency virus type 1 reverse transcriptase by tetrahydroimidazo[4,5,1-jk][1,4]benzodiazepin-2(1H)-one and -thione compounds.
Debyser Z; Pauwels R; Andries K; Desmyter J; Engelborghs Y; Janssen PA; De Clercq E
Mol Pharmacol; 1992 Jan; 41(1):203-8. PubMed ID: 1370707
[TBL] [Abstract][Full Text] [Related]
18. A mutation in reverse transcriptase of bis(heteroaryl)piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors.
Dueweke TJ; Pushkarskaya T; Poppe SM; Swaney SM; Zhao JQ; Chen IS; Stevenson M; Tarpley WG
Proc Natl Acad Sci U S A; 1993 May; 90(10):4713-7. PubMed ID: 7685109
[TBL] [Abstract][Full Text] [Related]
19. Enzymatic properties and sensitivity to inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase with Glu-138-->Arg and Tyr-188-->His mutations.
Zhang H; Vrang L; Bäckbro K; Unge T; Noréen R; Oberg B
Antiviral Res; 1994 May; 24(1):43-57. PubMed ID: 7524439
[TBL] [Abstract][Full Text] [Related]
20. Effect of a thiobenzimidazolone derivative on DNA strand transfer catalyzed by HIV-1 reverse transcriptase.
Gopalakrishnan V; Benkovic S
J Biol Chem; 1994 Feb; 269(6):4110-5. PubMed ID: 7508439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
